Summary A method to determine the binding of epidermal growth factor (EGF) to the particulate fraction of the cell has been established and evaluated using rat liver, human placenta, and tumours of human breast and brain. Little EGF receptor (EGFR) activity was detected in normal or benign tumour tissues except for meningioma (positive in 95% samples), but EGFR were present in 43% of 131 breast tumours and 75% of 55 primary cerebral tumours. Despite the strong inverse correlation between EGFR activity and oestrogen receptors in breast tumours and a tendency for high levels of EGFR activity to be associated with glioblastoma multiforme, analysis showed that EGFR was of little prognostic significance in patients with tumours of either breast or brain.
Recent advances in our understanding of the ways in which alterations in DNA can lead to cancer have suggested two major mechanisms (Ponder, 1988) namely (1) the overactivity of certain genes ('oncogenes') involved in transducing the signals for growth and (2) the loss of other genes ('tumour suppressor' or 'anti-oncogenes') which regulate differentiation and limit growth. One putative component of the former mechanism is epidermal growth factor (EGF), a small (Mr 6,045) peptide which acts through a larger, cell-surface receptor protein (EGFR, Mr 180,000). This receptor protein is structurally related to the product of a known oncogene (v-erb B,) . Potentially, overexpression of either the growth factor or its receptor could contribute to the process of carcinogenesis. Reports in the literature have suggested that over-expression of the receptor protein may occur in several types of tumour (Neal et al., 1985; Hwang et al., 1986; Cowley et al., 1986) , including those of the brain (Lieberman et al., 1985) and breast (Sainsbury et al., 1985) . Whether the growth factor or its receptor are involved in carcinogenesis in man is as yet unclear.
In established breast tumours, expression of the EGF receptor protein has been reported to be an index of poor prognosis (Sainsbury et al., 1985; , likelihood of lymph node involvement (Battaglia et al., 1988) and lack of response to endocrine therapy (Nicholson et al., 1989) . The expression of EGF receptors shows a strong inverse correlation with that of oestrogen receptors (Sainsbury et al., 1985; Perez et al., 1984; Delarue et al., 1988) and thus to some extent, measurements of EGFR may provide the same information as that derived from ER measurements.
In malignant gliomata, over-expression of the EGFR protein appears to be associated with gene amplification (Wong et al., 1987) . In culture, the growth of glial tumour cells can be stimulated by EGF (Frappaz et al., 1988) and antibodies against the EGFR can inhibit such stimulation (Werner et al., 1988) . Clinically, an antibody against the EGFR, labelled with 'l3I, has been reported to have induced significant regression of a glioma in a young man (Epenetos et al., 1985) , though the specificity of this effect is uncertain.
In view of the above considerations, we set out (1) to measure the levels of EGFR activity in series of intracranial and breast tumours and (2) to relate these findings to the patient's outcome. In view of the established significance of the oestrogen receptor (Knight et al., 1977; Adami et al., 1985) , we have also examined the results for this protein in the breast tumours.
Materials and methods

Radiochemicals
Initially, 125I iodide, was purchased from Amersham International, Little Chalfont, Bucks. and used to prepare '25I EGF. A total of 19 iodinations were carried out using either iodogen (Fraker & Speck, 1978 ; n = 16) or lactoperoxidase (Thorell & Johnson, 1971 ; n = 3). The radioactive EGF thus prepared was stored in aliquots at -40°C until required, for up to 1 month. The specific radioactivity of the preparations used ranged from 76 to 196 gsCi Ag' i.e. 2.8-7.3 MBq ig-'. Because of the unpredictability of these iodinations in our hands, we changed over to purchasing the radioligand.
1251 EGF Cat. No NEX-160) was purchased from Du Pont (UK) Ltd, Wedgewood Way, Stevenage, Herts. and used without repurification.
[2,4,6,7-3H]oestradiol-17P Burger et al. (1985) and Russell and Rubenstein (1989) .
In 11 patients, specimens of normal, peri-tumoral brain were available from the material excised at operation (eight specimens from patients where tumour was also available and three where no other tissue was available). The remaining 85 abnormal tissues included 51 gliomata which were further divided into 47 commoner types and four rarer types.
Follow-up time for all these patients ranged from 1-105 months (median 9 months). Follow-up was analysed only for the 51 patients with tumours of the commoner types, i.e. 47 commoner gliomata and four primitive neuro-ectodermal tumours (PNETs), since the natural history of meningiomas and schwannomas necessitates long-term follow-up to document recurrence (Simpson, 1957) . In these patients, surgery was by craniotomy and debulking in all patients except one with a PNET who had craniotomy and biopsy only.
(b) With tumours of the breast For 151 female patients undergoing surgery for a lesion of the breast between 16-09-86 and 24-06-88, a specimen was submitted for oestrogen receptor analysis and sufficient material was present for the additional assay of EGFR. Of these patients, nine had benign lesions, one had a melanoma, five had specimens containing an inadequate sample (< 10%) of tumour (Steele et al., 1987) Determination of EGF receptor activity The method used is based on that of Sainsbury et al. (1985) . After examination of the steps involved in the assay separately, the following procedure was adopted routinely.
( 0.024, 0.049, 0.098, 0.195, 0.39, 0.78, 1.56, 3.125, 6.25, 12.5, 25.0, 50.0, 100.0 (3) Termination All tubes were placed on ice and to each was added 0.5 ml of immunoglobulin G solution (0.5% w/v) and 1.0ml of polyethylene glycol solution (25% v/v) with mixing between the additions. The tubes were remixed and centrifuged immediately for 15 min at 2,100 g in the swingout-rotor of a precooled, MSE Mistral 6L centrifuge. After centrifugation, the supernatant (free) fraction was aspirated from each tube and the remaining pellet (bound) was counted for 2 x 10 min in a Packard Multi-Prias Gamma Counter at approximately 70% efficiency. Three tubes containing only 1251I EGF ('radioligand') were also counted to yield the starting c.p.m./tube. (4) Calculation of receptor site concentration After correction of the counts bound in each tube by subtraction of the value for non-specific binding (300 nMolar tube), the data were subjected to Scatchard (1949) analysis. Non-specific binding averaged 8.9% of the total radioligand added (n = 30). EGFR activity was designated as positive when > 150 c.p.m. were displaced over at least four of 15 tubes by non-radioactive EGF in the initial (high affinity) part of the curve. Where no displacement was evident, the tissue was designated EGFR -negative. Cases showing only a small displacement and where a Scatchard plot was not possible were designated as 'EGFR equivocal'. For quantitative purposes, routinely curves were drawn by hand and extrapolated to the horizontal axis to yield an estimate of the total binding sites (high + low affinity sites) present. Subsequently we examined many of the plots by the computer-analysis method of Hetherington (Sainsbury et al., 1985; Nicholson et al., 1988) to assign, fit and calculate both the slopes and x-axis intercepts where two components were present. Retrospective comparison of the extrapolation method with the computer -analysis method showed very little error (total sites from extrapolation = 98.1% value from computer analysis, n = 17 assays on rat liver membranes). 'EGFR -equivocal' tissues were arbitrarily assigned a total receptor site concentration of 5 fmol mg'-membrane protein, though in some EGFR -positive tissues, values as low as 1 fmol mg-' membrane protein were derived by calculation.
A sample of rat liver membranes was processed, as a quality control, with each batch of samples. These membranes, prepared in bulk and stored in aliquots at -40°C, lost activity gradually on storage (approx 47% over 10 months) but were nevertheless useful. The inter-assay coefficient of variation for total sites in rat liver (measured over only 1 month) was 21% (n=6), 38% (n=7), 23% (n=6), and 30% (n = 6) for four different months, the mean loss of activity being 4.7% per month on storage.
In preliminary experiments, we investigated (a) the influence of the subcellular fraction chosen on binding, (b) three different methods for separating free and bound peptide, (c) the influence of time and temperature on binding and (d) the specificity of the binding observed.
Determination of oestrogen receptor activity Oestrogen receptor activity was determined by the method of Hawkins et al. (1975 Hawkins et al. ( , modified 1981 on the supernatant remaining from EGFR assay or prepared by homogenisation of a separate, adjacent portion of tissue. The data were analysed according to Scatchard (1949) using a BBC microcomputer to yield the dissociation constant of binding (Kd nmols I') and receptor site concentration (fmols mg' soluble protein)., Quality controls, consisting of pools of minced human myometrium were processed with every assay and the interassay coefficients of variation were 17.0% (n = 48) at high levels (111 fmol mg-' protein) and 25.5% (n = 144) at lower levels (48 fmol mg-' protein).
Determination ofprotein concentration The protein contents of membrane preparations were determined after dissolution in 2 N sodium hydroxide solution and neutralisation with 2 N HCI solution, by assay with Coomassie Blue reagent (Bradford, 1976 ) against a mixed protein standard (Sigma, Cat. No 540-10). Tissue extracts ('cytosols') were assayed directly. Five quality control samples were processed with each assay and where the mean value deviated by more than 10% from the expected, the assay was repeated.
Statistical evaluations
The inter-relationship between oestrogen and epidermal growth factor receptor activities was examined by Kendall's Rank Correlation Coefficient. The inter-relationship was also examined by classifying breast tumours as EGFR-positive ( > 1 fmol mg-' protein) or EGFR-negative, and ER-positivity according to various cut-offs (5, 10, 15, 20, 30, 50 and lOOfmolmg'I protein). Cohen's kappa was then calculated (Cohen, 1960) to give a measure of the concordance between EGFR-positivity and ER-negativity.
In order to examine the importance of each receptor activity in relation to prognosis (disease-free interval and survival for breast tumours, survival for brain tumours), Cox's proportional hazards regression model was applied in firstly, univariate and secondly, multivariate analyses. (Figure 3a) . In a breast tumour (Figure 3b) Figure 1 . Inspection of the plot revealed evidence for two binding compontents in some tissues (rat liver always, others more variable) and one in others. When the data were analysed by computer, the Kds of the high and low affinity components were in the ranges of 0.01-0.50 nM and 1.0-5.0 nM respectively (see Figure 2 ), though the affinity in some brain tumours was apparently rather different (see Discussion).
Since (1) initially we did not have the computer program for separating the two components (2) there is no conclusive evidence that lower affinity sites are of no significance, in the results which follow, concentration of total receptor sites has been calculated by extrapolation, unless stated otherwise.
Influence of mode ofseparating free and bound ligand A comparison of three different methods for separating free and bound ligand was carried out on rat liver membranes. The methods were (A) simple centrifugation of the membranes (Sainsbury et al., 1985) (B) filtration of the membranes (based on Fitzpatrick et al., 1984) and (C) co-precipitation of IgG with polyethylene glycol (based on Carpenter, 1985) . This showed that by method C, on average, slightly lower Kd values (stronger binding) for both low and high affinity components (ratios of Kdl by methods A: B: C = 3.49: 3.86: 1.00; Kd2= 1.82: 1.89: 1.00, means of four experiments by computer analysis) and higher numbers of total receptor sites (ratios A: B: C = 0.78: 0.87: 1.00) were observed than were found by methods A or B. The Kd, and Kd2 values found by this method, C, were also more consistent and this method was selected for the routine procedure.
Influence ofsubcellular fraction analysed When the total homogenate was separated by centrifugation into subcellular fractions, binding activity was found in all the particulate subcellular fractions (Table I) . This was especially evident in rat liver and brain tumours of the three types of tissue examined. In view of this finding, for routine purposes, we collected all the particulate fractions ('membranes') of the cell for assay, by a single centrifugation at 108,000 g. 1.6 A = sum of total receptor sites derived by extrapolation of a Scatchard plot for each fraction, expressed as fmol sites mg-' wet tissue; B = 'nuclei/debris', 800 g pellet; C ='low speed membranes', 800-2,000 g pellet; D ='high speed membranes', 2,000 -108,000 g pellet; E = 'cytosol', 108,000 g supernatant.
relation between the presence of ER and that of EGFR (Kendall's R = -0.35, P<0.001). By Cohen's Kappa test, this inverse relationship was strongest (Cohen's Kappa 0.52-0.53) when a cut-off of 10-15 fmol mg' protein was used to designate 'presence/absence' for the oestrogen receptor.
At analysis, there had been 43 recurrences and 30 deaths. When the relationship of the various clinical or biochemical parameters to disease-free interval or survival was examined by univariate analysis, only node status, tumour stage, tumour size and oestrogen receptor concentration had a significant influence (Table II) . By multivariate analysis, only node status and oestrogen receptor concentration influenced prognosis (Table III) . No clear relationship was shown between EGFR activity and prognosis whilst higher levels of ER activity (>100 fmol mg-' protein) were associated with a longer disease-free interval (survival curves not shown).
Incidence and significance of EGFR in brain tissue EGFR activity was detectable in only one of 11 samples of normal brain (9%), in 1/6 schwannomas (16%), 20/21 samples of meningioma (95%, median level 155 fmol mg-' protein), in 2/3 metastatic deposits from extracranial malignant tumours and in 41/55 intracranial tumours (75%, median level 44 fmol mg ' protein). Within the gliomata, there were marked differences between the levels of EGFR activity in the different histopathological types of tumour (Table IV) , with very high levels being detected in some samples of glioblastoma multiforme.
By univariate analysis, the patient's age, tumour type and mode of primary treatment were significantly related to survival (Table V) whilst sex, type of specimen (10 or recurrence) assayed and EGFR concentration had no influence. Patients who were younger at presentation fared better than those presenting later and survival related to tumour histological type in the manner expected, i.e. increasing survival in the order (1) glioblastoma multiforme, (2) anaplastic astrocytoma, (3) oligodendroglioma/mixed oligo-astrocytoma, (4) PNET and (5) astrocytoma. In addition, patients treated by surgery alone fared less well than those receiving combined treatments.
Even though patients with high levels of EGFR activity appeared to fare worse than those with lower levels (e.g. Figure 4a ), this effect was due to the association between high levels of EGFR activity and a particualr tumour type (glioblastoma multiforme) and the apparent influence of EGFR level on survival disappeared when only a single tumour type was considered (Figure 4b) . By multivariate analysis, again only age, tumour type and mode of treatment influenced survival (Table VI) and bound hormone by co-precipitation, and to measure the total receptor site concentration present in the total particulate fraction of the cell. Others have used a variety of ligand-binding methods (e.g. Nicholson et al., 1988) , or an autophosphorylation method (Lieberman et al., 1985) , and slightly different subcellular fractions (e.g. Sainsbury et al., 1985; Fitzpatrick et al., 1984; Perez et al., 1984) . Most tissues, in our experience, demonstrated both high and low affinity binding sites; since the significance of these two types of site is unclear, though it might relate to the degree of aggregation of the EGFR monomers (Schlessinger, 1988) (Whittle et al., 1987; Horsfall et al., 1989) . Maligant tumours of the breast contained some binding activity in 43% of the 131 tumours examined, whilst those of the brain contained activity in 75% of the 55 intracranial cases.
In the case of breast cancer, our study population was a mixture of patients at all stages in the course of the disease, treated at nine different hospitals. They represent a group of patients with larger tumours and a poor prognosis; there were 43 recurrences and 30 deaths in the relatively short follow-up period, and only 63% of the tumours contained detectable ER activity (c.f. > 75% in unselected patients in our experience . By both univariate and multivariate analyses, in contrast to the findings of the Newcastle group (Sainsbury et al., 1985 (Sainsbury et al., , 1987 Nicholson et al., 1989) , EGFR measurements were of no prognostic value and only node status and ER measurements related significantly to disease-free interval or survival (Table III) . However, it is to be noted that EGFR and ER show a strong inverse relationship, and thus to some extent, they provide the same information. The reasons for the difference between our findings and the previous reports are not clear but they could relate to (1) insufficient sensitivity in our EGFR assay, particularly where only small samples of tumour were available, (2) our study of total EGFR sites (c.f. high affinity sites by the Newcastle workers), though this seems unlikely since EGFR + tissues generally contained high affinity sites and (3) the fact that the tumours studied constitute a selected group which is probably not representative of the spectrum of breast cancers. Other workers have also examined the prognostic value of EGFR measurements but the results have been contradictory. Grimaux et al. (1989) , examining a small subgroup of 55 patients, found that EGFR status was an important prognostic factor by both univariate and multivariate analyses at 40 months of follow-up. By contrast, Foekens et al. (1989) , in a larger group of 214 patients, found that, as in the present study, steroid receptor status, but not EGFR status, was of prognostic value. For brain tumours, to our knowledge, the prognostic value of EGFR measurements has not been examined previously. In the present series, although there was a tendancy for tumours of the most aggressive histological type (glioblastoma multiforme) to produce high levels of EGFR, multivariate analysis revealed that only age, histopathological tumour type and type of treatment related to survival.
Our findings of high levels of expression of EGFR by some gliomata are in agreement with those of others (Liebermann et al., 1985; Wong et al., 1987; Helseth et al., 1988) . This overexpression has been found frequently to be associated with gene amplification (Liebermann et al., 1985; Helseth et al., 1988) and the process appeared to confer a growth advantage upon suspensions of single cells from human gliomata, grown in agar (Helseth et al., 1988) . Glioma cell lines in culture are, in some cases, sensitive to EGF and can be inhibited by an antibody against the EGFR (Werner et al., 1988) . In vivo, four of seven patients with recurrent gliomata localised by immunoscintigraphy using '25I-labelled antibodies against EGFR and treated with "3'N-labelled antibody have shown clinical improvement (Kalofonos et al., 1989) . Despite these observations, Collins (Collins, P. Swedenpersonal communication to I.R.W.), in line with our own findings on EGFR expression, found no correlation between EGFR gene amplification and survival.
In summary, we conclude that the EGFR protein tends to be expressed in malignant tumours of poorer prognosis in both breast and brain. However, the extent of this expression in variable and not sufficiently consistent, by our mode of analysis, to be of prognostic significance. Re-examination of this question with a more sophisticated and sensitive assay or in a wider spectrum of breast cancers could alter that conclusion. 
